Results from a clinical trial suggest that 177Lu-Dotatate may soon be a new treatment option for some patients with advanced neuroendocrine tumors.
Month: February 2017
Study suggests it outweighs obesity and family history, but oncologists say more research is needed
Study estimates nearly 15,000 lives saved over decade if all who needed hormone treatment got it
A new study by the Cancer Target Discovery and Development Network identified XPO1 as a vulnerability specific to KRAS-mutant lung cancers that responds to available drugs. Paired with genomics-based patient selection, this finding could improve lung cancer care.
Such testing could cut death rate by 20 percent, American Cancer Society says
But, newer and possibly more effective drugs now available and being studied
A fact sheet that summarizes evidence linking exercise and other physical activity, including work and household chores, to reduced cancer risks.
A fact sheet that summarizes the evidence linking overweight and obesity to the risk of various cancers and to cancer survivorship.
CGH is pleased to welcome the third cohort of investigator teams to the Affordable Cancer Technologies Program.
The Affordable Cancer Technologies Program promotes the development and validation of low-cost, portable technologies.